Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease

References

• TBurisch J Jess, MMartinato, PLLakatos; ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013;4:322–37.
   Google Scholar
• BKhor, AGardet, RJXavier. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474:307–17.
   PubMed Web of Science ®Google Scholar
• MFNeurath. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014;14:329–42.
   PubMed Web of Science ®Google Scholar
• HMvan Dullemen, SJvan Deventer, DWHommes, HABijl, JJansen, GNTytgat, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129–35.
   PubMed Web of Science ®Google Scholar
• SRTargan, SBHanauer, SJvan Deventer, LMayer, DHPresent, TBraakman, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997;337:1029–35.
   PubMed Web of Science ®Google Scholar
• PRutgeerts, WJSandborn, BGFeagan, WReinisch, AOlson, JJohanns, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.
   PubMed Web of Science ®Google Scholar
• WJSandborn, Gvan Assche, WReinisch, JFColombel, GD’Haens, DCWolf, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257–65.
   PubMed Web of Science ®Google Scholar
• JFColombel, WJSandborn, PRutgeerts, REnns, SBHanauer, RPanaccione, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• WJSandborn, SDLee, CRandall, AGutierrez, DASchwartz, SAmbarkhane, et al. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn’s disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther 2014;40:903–16.
   PubMed Web of Science ®Google Scholar
• XHébuterne, MLémann, YBouhnik, ODewit, JLDupas, MMross, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease following treatment with certolizumab pegol. Gut 2013;62:201–8.
   PubMed Web of Science ®Google Scholar
• WJSandborn, JFColombel, REnns, BGFeagan, SBHanauer, ICLawrance, et al. International Efficacy of Natalizumab as Active Crohn’s Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005;353:1912–25.
   PubMed Web of Science ®Google Scholar
• BGFeagan, PRutgeerts, BESands, SHanauer, JFColombel, WJSandborn, et al. GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699–710.
   PubMed Web of Science ®Google Scholar
• PKawalec, AMikrut, NWiśniewska, APilc. Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn’s disease: systematic review and meta-analysis. Arch Med Sci 2013;9:765–79.
   PubMed Web of Science ®Google Scholar
• SMozaffari, SNikfar, AHAbdolghaffari, MAbdollahi. New biologic therapeutics for ulcerative colitis and Crohn’s disease. Expert Opin Biol Ther 2014;14:583–600.
   PubMed Web of Science ®Google Scholar
• FSchnitzler, HFidder, MFerrante, MNoman, IArijs, GVan Assche, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis 2009;15:1295–301.
   PubMed Web of Science ®Google Scholar
• SPTravis, PDHiggins, TOrchard, CJVan Der Woude, RPanaccione, ABitton, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011;34:113–24.
   PubMed Web of Science ®Google Scholar
• GRLichtenstein, PRutgeerts. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010;16:338–46.
   PubMed Web of Science ®Google Scholar
• PDe Cruz, MAKamm, LPrideaux, PBAllen, GMoore. Mucosal healing in Crohn’s disease: a systematic review. Inflamm Bowel Dis 2013;19:429–44.
   PubMed Web of Science ®Google Scholar
• PRutgeerts, et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn’s disease – first results of the EXTEND Trial. Gastroenterology 2009;136:A-116.
   Web of Science ®Google Scholar
• JRTurner. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009;9:799–809.
   PubMed Web of Science ®Google Scholar
• MFNeurath, SPTravis. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012;61:1619–35.
   PubMed Web of Science ®Google Scholar
• TKarrasch, CJobin. Wound healing responses at the gastrointestinal epithelium: a close look at novel regulatory factors and investigative approaches. Z Gastroenterol 2009;47:1221–9.
   PubMed Web of Science ®Google Scholar
• PDe Cruz, MAKamm, LPrideaux, PBAllen, GMoore. Mucosal healing in Crohn’s disease: a systematic review. Inflamm Bowel Dis 2013;19:429–44.
   PubMed Web of Science ®Google Scholar
• CZallot, LPeyrin-Biroulet. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep 2013;15:315.
   PubMedGoogle Scholar
• SVavricka, ASchoepfer, PLLakatos. Mucosal healing and deep remission: what does it mean? World J Gastroenterol 2013;19:7552–60.
   PubMed Web of Science ®Google Scholar
• RRismo, TOlsen, GCui, EJPaulssen, IChristiansen, KJohnsen, et al. Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn’s disease. Scand J Gastroenterol 2013;48:311–19.
   PubMed Web of Science ®Google Scholar
• MParlato, GYeretssian. NOD-like receptors in intestinal homeostasis and epithelial tissue repair. Int J Mol Sci 2014;15:9594–627.
   PubMed Web of Science ®Google Scholar
• BBaum, MGeorgiou. Dynamics of adherens junctions in epithelial establishment, maintenance, and remodeling. J Cell Biol 2011;192:907–17.
   PubMed Web of Science ®Google Scholar
• ARavi, PGarg, SVSitaraman. Matrix metalloproteinases in inflammatory bowel disease: boon or a bane? Inflamm Bowel Dis 2007;13:97–107.
   PubMed Web of Science ®Google Scholar
• GLatella, GRogler, GBamias, CBreynaert, JFlorholmen, GPellino, et al. Results of the 4th scientific workshop of the ECCO (I): Pathophysiology of intestinal fibrosis in IBD. J Crohns Colitis 2014;8:1147–65.
   PubMed Web of Science ®Google Scholar
• MBonyadi, RAbdolmohammadi, ZJahanafrooz, MHSomy, MKhoshbaten. TNF-alpha gene polymorphisms in Iranian Azari Turkish patients with inflammatory bowel diseases. Saudi J Gastroenterol 2014;20:108–12.
   PubMed Web of Science ®Google Scholar
• DQShih, SRTargan. Insights into IBD Pathogenesis. Curr Gastroenterol Rep 2009;11:473–80.
   PubMedGoogle Scholar
• GSabio, RJDavis. TNF and MAP kinase signalling pathways. Semin Immunol 2014;26:237–45.
   PubMed Web of Science ®Google Scholar
• JWei, JFeng. Signaling pathways associated with inflammatory bowel disease. Recent Pat Inflamm Alergy Drug Discov 2010;4:105–17.
   PubMedGoogle Scholar
• AKaser, SZeissig, RSBlumberg. Genes and environment: how will our concepts on the pathophysiology of IBD develop in the future? Dig Dis 2010;28:395–405.
   PubMed Web of Science ®Google Scholar
• TOlsen, RGoll, GCui, AHusebekk, BVonen, GSBirketvedt, et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol 2007;42:1312–20.
   PubMed Web of Science ®Google Scholar
• MLeppkes, MRoulis, MFNeurath, GKollias, CBecker. Pleiotropic functions of TNF-alpha in the regulation of the intestinal epithelial response to inflammation. Int Immunol 2014;26:509–15.
   PubMed Web of Science ®Google Scholar
• FWang, WVGraham, YWang, EDWitkowski, BTSchwarz, JRTurner. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol 2005;166:409–19.
   PubMed Web of Science ®Google Scholar
• DRGreen, AOberst, CPDillon, RWeinlich, GSSalvesen. RIPK-dependent necrosis and its regulation by caspases: a mystery in five acts. Mol Cell 2011;44:9–16.
   PubMed Web of Science ®Google Scholar
• JCorredor, FYan, CCShen, WTong, SKJohn, GWilson, et al. Tumor necrosis factor regulates intestinal epithelial cell migration by receptor-dependent mechanisms. Am J Physiol Cell Physiol 2003;284:C953–61.
   Web of Science ®Google Scholar
• EMizoguchi, AMizoguchi, HTakedatsu, ECario, YPde Jong, et al. Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology 2002;122:134–44.
   PubMed Web of Science ®Google Scholar
• VCHilliard, MRFrey, PJDempsey, RMPeekJr, DBPolk. TNF-alpha converting enzyme-mediated ErbB4 transactivation by TNF promotes colonic epithelial cell survival. Am J Physiol Gastrointest Liver Physiol 2011;301:G338–46.
   Web of Science ®Google Scholar
• SSchwitalla, AAFingerle, PCammareri, TNebelsiek, SIGöktuna, PKZiegler, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013;152:25–38.
   PubMed Web of Science ®Google Scholar
• GRogler, SVavricka, ASchoepfer, PLLakatos. Mucosal healing and deep remission: what does it mean? World J Gastroenterol 2013;19:7552–60.
   PubMed Web of Science ®Google Scholar
• MDaperno, FCastiglione, Lde Ridder, IDotan, MFärkkilä, JFlorholmen, et al. Scientific Committee of the European Crohn’s and Colitis Organization. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis 2011;5:484–98.
   PubMed Web of Science ®Google Scholar
• CPagnini, FMenasci, SFesta, GRizzatti, GDelle Fave. “Mucosal healing” in ulcerative colitis: Between clinical evidence and market suggestion. World J Gastrointest Pathophysiol 2014;5:54–62.
   PubMedGoogle Scholar
• JYMary, RModigliani. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30:983–9.
   PubMed Web of Science ®Google Scholar
• MDaperno, GD’Haens, GVan Assche, FBaert, PBulois, VMaunoury, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 2004;60:505–12.
   PubMed Web of Science ®Google Scholar
• XHébuterne, MLémann, YBouhnik, ODewit, JLDupas, MMross, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease following treatment with certolizumab pegol. Gut 2013;62:201–8.
   PubMed Web of Science ®Google Scholar
• KWSchroeder, WJTremaine. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625–9.
   PubMed Web of Science ®Google Scholar
• JFColombel, PRutgeerts, WReinisch, DEsser, YWang, YLang, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194–201.
   PubMed Web of Science ®Google Scholar
• SPTravis, DSchnell, PKrzeski, MTAbreu, DGAltman, JFColombel, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61:535–42.
   PubMed Web of Science ®Google Scholar
• BIKorelitz, SCSommers. Response to drug therapy in Crohn’s disease: evaluation by rectal biopsy and mucosal cell counts. J Clin Gastroenterol 1984;6:123–7.
   PubMed Web of Science ®Google Scholar
• BIKorelitz. Mucosal healing as an index of colitis activity: back to histological healing for future indices. Inflamm Bowel Dis 2010;16:1628–30.
   PubMed Web of Science ®Google Scholar
• FHartmann, JStein; BudMesa-Study Group. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2010;32:368–76.
   PubMed Web of Science ®Google Scholar
• WKruis, GKiudelis, IRácz, IAGorelov, JPokrotnieks, MHorynski, et al. International Salofalk OD Study Group. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009;58:233–40.
   PubMed Web of Science ®Google Scholar
• ABressenot, KGeboes, JMVignaud, JLGuéant, LPeyrin-Biroulet. Microscopic features for initial diagnosis and disease activity evaluation in inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1745–52.
   PubMed Web of Science ®Google Scholar
• LPeyrin-Biroulet, ABressenot, WKampman. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol 2014;12:929–34.
   PubMed Web of Science ®Google Scholar
• GRLichtenstein, PRutgeerts. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010;16:338–46.
   PubMed Web of Science ®Google Scholar
• KLIsaacs. How rapidly should remission be achieved? Dig Dis 2010;28:548–55.
   PubMed Web of Science ®Google Scholar
• CGheorghe, BCotruta, RIacob, GBecheanu, MDumbrava, LGheorghe. Endomicroscopy for assessing mucosal healing in patients with ulcerative colitis. Gastrointestin Liver Dis 2011;20:423–6.
   PubMed Web of Science ®Google Scholar
• GD’Haens, WJSandborn, BGFeagan, KGeboes, SBHanauer, EJIrvine, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763–86.
   PubMed Web of Science ®Google Scholar
• AStallmach, TGiese, CSchmidt, BLudwig, IMueller-Molaian, SCMeuer. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn’s disease. Int J Colorectal Dis 2004;19:308–15.
   PubMedGoogle Scholar
• TOlsen, GCui, RGoll, AHusebekk, JFlorholmen. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol 2009;44:727–35.
   PubMed Web of Science ®Google Scholar
• RRismo, TOlsen, GCiu, EJPaulssen, IChristiansen, JFlorholmen, et al. The effect of adalimumab for induction of endoscopic healing and normalization of mucosal cytokine gene expression in Crohn’s disease. Scand J Gastroenterol 2012;47:1200–10.
   PubMed Web of Science ®Google Scholar
• MKarlsson, LLinton, MLampinen, PKarlén, HGlise, RBefrits, et al. Naïve T cells correlate with mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2014;49:66–74.
   PubMed Web of Science ®Google Scholar
• JGrundström, LLinton, SThunberg, HForsslund, IJanczewska, RBefrits, et al. Altered immunoregulatory profile during anti-tumour necrosis factor treatment of patients with inflammatory bowel disease. Clin Exp Immunol 2012;169:137–47.
   PubMed Web of Science ®Google Scholar
• GRD’Haens, RBSartor, MSSilverberg, JPetersson, PRutgeerts. Future directions in inflammatory bowel disease management. J Crohns Colitis 2014;8:726–34.
   PubMed Web of Science ®Google Scholar
• TLobaton, SVermeire, GVan Assche, PRutgeerts. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2014;39:579–94.
   PubMed Web of Science ®Google Scholar
• RNoth, EStüber, RHäsler, SNikolaus, TKühbacher, JHampe, et al. Anti-TNF-alpha antibodies improve intestinal barrier function in Crohn’s disease. J Crohns Colitis 2012;6:464–9.
   PubMed Web of Science ®Google Scholar
• AFischer, MGluth, UFPape, BWiedenmann, FTheuring, DCBaumgart. Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-alpha on tight junction proteins and signaling pathways in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2013;304:G970–9.
   PubMed Web of Science ®Google Scholar
• PRutgeerts, BGFeagan, GRLichtenstein, LFMayer, SSchreiber, JFColombel, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004;126:402–13.
   PubMed Web of Science ®Google Scholar
• JFColombel, WJSandborn, WReinisch, GJMantzaris, AKornbluth, DRachmilewitz, et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383–95.
   PubMed Web of Science ®Google Scholar
• PRutgeerts, GVan Assche, WJSandborn, DCWolf, KGeboes, JFColombel, et al. EXTEND Investigators. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology 2012;142:1102–11.
   PubMed Web of Science ®Google Scholar
• Adalimumab in the treatment of moderate-to-severe ulcerative colitis: ULTRA 2 trial results. Gastroenterol Hepatol (N Y) 2013;9:317–20.
   PubMedGoogle Scholar
• JFColombel, WJSandborn, SGhosh, DCWolf, RPanaccione, BFeagan, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol 2014;109:1771–80.
   PubMed Web of Science ®Google Scholar
• RWright, SRTruelove. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966;11:847–57.
   PubMedGoogle Scholar
• KFFrøslie, JJahnsen, BAMoum, MHVatn; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412–22.
   PubMed Web of Science ®Google Scholar
• ICSolberg, ILygren, JJahnsen, EAadland, OHøie, MCvancarova, et al. IBSEN Study Group. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009;44:431–40.
   PubMed Web of Science ®Google Scholar
• JFColombel, PRutgeerts, WReinisch, DEsser, YWang, YLang, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194–201.
   PubMed Web of Science ®Google Scholar
• PRutgeerts, RHDiamond, MBala, AOlson, GRLichtenstein, WBao, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 2006;63:433–42.
   PubMed Web of Science ®Google Scholar
• FBaert, LMoortgat, GVan Assche, PCaenepeel, PVergauwe, MDe Vos, et al. Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 2010;138:463–8.
   PubMed Web of Science ®Google Scholar
• VCrombé, JSalleron, GSavoye, JLDupas, GVernier-Massouille, ELerebours, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn’s disease: a population-based study. Inflamm Bowel Dis 2011;17:2144–52.
   PubMed Web of Science ®Google Scholar
• SPLTravis, PDHiggins, TOrchard, CJVan Der Woude, RPanaccione, ABitton, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011;34:113–24.
   PubMed Web of Science ®Google Scholar
• RBGupta, NHarpaz, SItzkowitz, SHossain, sMatula, AKornbluth, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007;133:1099–105.
   PubMed Web of Science ®Google Scholar
• CZallot, LPeyrin-Biroulet. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep 2013;15:0315–17.
   PubMedGoogle Scholar
• BIKorelitz, KSultan, MKothari, LArapos, JSchneider, GPanagopoulos. Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. World J Gastroenterol 2014;20:4980–6.
   PubMed Web of Science ®Google Scholar
• JFColombel, PRutgeerts, WReinisch, DEsser, YWang, YLang, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerativecolitis. Gastroenterology 2011;141:1194–201.
   PubMed Web of Science ®Google Scholar
• GD’Haens, FBaert, Gvan Assche, PCaenepeel, PVergauwe, HTuynman, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008;371:660–7.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Infliximab (review) and Adalimumab for the treatment of Crohn’s disease. NICE technology appraisal guidance 187. 2010. p 4–5. Available from: http://guidance.nice.org.uk/TA187.
   Google Scholar
• ELouis, JYMary, GVernier-Massouille, JCGrimaud, YBouhnik, DLaharie, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63–70.
   PubMed Web of Science ®Google Scholar
• CSteenholdt, AMolazahi, MAAinsworth, JBrynskov, OOThomsen, JBSeidelin. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol 2012;47:518–27.
   PubMed Web of Science ®Google Scholar
• AWWaugh, SGarg, KMatic, LGramlich, CWong, DCSadowski, et al. Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010;32:1129–34.
   PubMed Web of Science ®Google Scholar
• KMJohnsen, VHansen, JFlorholmen, RGoll, TOlsen. Twelve years prospective study of infliximab treatment in ulcerative colitis performing and algorithm of repeated intensive induction therapies to remission and biomarkers for long term remission without need of infliximab [abstract]. United European Gastroenterol J 2014, 2 (1Suppl), A536.
   Google Scholar
• BPariente, DLaharie. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2014;40:338–53.
   PubMed Web of Science ®Google Scholar
• LRosenberg, KSNanda, TZenlea, AGifford, GOLawlor, KRFalchuk, et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol 2013;11:991–6.
   PubMed Web of Science ®Google Scholar
• CGuanglin, TOlsen, IChristiansen, BVonen, JFlorholmen, RGoll. Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: An approach to optimize procedures for clinical use. Scand J Clin Lab Invest 2006;66:249–60.
   PubMed Web of Science ®Google Scholar
• RPaulssen, RGoll, JFlorholmen. Towards a cure. Technology & Science, Pan European Network Ltd, Congleton, United Kingdom; 2014. p 178–9.
   Google Scholar